A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab

Furui, Yu; Kurata, Takeshi; Komori, Kazutoshi; Uchida, Eiji; Miyairi, Yosuke; Chibá, Akira; Ogiso, Yoshifumi; Sakashita, Kazuo

doi:10.1007/s13691-022-00562-x

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient achieved a significant symptom reduction without palliative radiotherapy and has had a progression free survival with over 30 months. Pembrolizumab was tried in another patient in Japan with a response in the primary tumor and bones, but new metastatic lesions also developed 17 . To our best knowledge, our patient is the first case with HS who had a durable response to pembrolizumab.…”

Section: Discussionmentioning

confidence: 99%

Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report

Nguyen,

Pham,

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Introduction and importance: Histiocytic sarcoma (HS) is an extremely rare malignancy in which there has been no standard treatment approach. Some preclinical studies have provided rationales for the application of immunotherapy in advanced HS. Case presentation We reported a case of a 61-year-old patient with metastatic HS who had a rapid progression on ifosfamide, carboplatin and etoposide chemotherapy. We performed PD-L1 testing which showed a strong positivity in 90% of tumor cells. The patient was then treated with pembrolizumab 200 mg every 3 weeks. He refused palliative radiotherapy. A dramatic response in all sites was recorded on PET-CT scan after 3 cycles. He was maintained on pembrolizumab, reaching over 30 months without disease progression. Clinical Discussion Recent molecular data suggests there could be a role of immunotherapy in histiocytic sarcoma. In our patient, the disease was refractory to chemotherapy and pembrolizumab has been given based on the strong PD-L1 expression. Response to immunotherapy has also been recorded in several cases with malignant histiocytic neoplasm. Conclusion Immunotherapy might bring sustained disease remission in PD-L1 high expression HS and further studies evaluating the role of immune checkpoint inhibitor in this disease are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report

Nguyen,

Pham,

et al. 2023

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

show abstract

Antineoplastics

2023

Reactions Weekly

View full text Add to dashboard Cite

Microsatellite Instability and Clinical Use in Sarcomas: Systematic Review and Illustrative Case Report

Fernandes,

Dias e Silva,

Segatelli

et al. 2024

JCO Precis Oncol

View full text Add to dashboard Cite

Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is approved for deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) tumors regardless of histology, there is a paucity of data to support its effectiveness in dMMR/MSI-H sarcomas. This study presents a case of a metastatic undifferentiated pleomorphic sarcoma of the retroperitoneum with dMMR status demonstrating a sustained complete response to pembrolizumab. Our case revealed inconsistencies in identifying dMMR/MSI-H status through next-generation sequencing, immunohistochemistry, and polymerase chain reaction methods. Therefore, we conducted a systematic review to analyze various methods for assessing dMMR/MSI-H and to explore whether pembrolizumab's indications rely on this biomarker.

show abstract

A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab

Cited by 4 publications

References 24 publications

Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report

Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report

Antineoplastics

Microsatellite Instability and Clinical Use in Sarcomas: Systematic Review and Illustrative Case Report

Contact Info

Product

Resources

About